Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of F-1515 (lutetium-177 oxodotreotide) plus F-1520 in somatostatin receptor–positive neuroendocrine tumors
jRCT2080223594Phase 1Completed
- Sponsor
- FUJIFILM Toyama Chemical
- Start
- Jul 2017
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluciclovine f 18 and lysine hydrochloride + arginine hydrochloride in islet cell tumor, gastrointestinal neuroendocrine neoplasm (GI-NEN) and bronchial neuroendocrine tumor, sponsored by FUJIFILM Toyama Chemical. Started Jul 2017; status: completed.
02
Drugs
fluciclovine f 18lysine hydrochloride + arginine hydrochloride
03
Conditions
islet cell tumorgastrointestinal neuroendocrine neoplasm (GI-NEN)bronchial neuroendocrine tumor
Beyond the preview
Go deeper on jRCT2080223594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223594.